In lung cancer, some studies indicate that diosmetin can selectively induce cell apoptosis through ROS accumulation by disrupting the PI3K/Akt/GSK-3β/Nrf2 pathway and enhance the efficacy of paclitaxel in NSCLC cells [14]. Here, GSK3B is linked to non-small cell lung carcinoma.